BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 24428392)

  • 1. F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma.
    Gallicchio R; Mansueto G; Simeon V; Nardelli A; Guariglia R; Capacchione D; Soscia E; Pedicini P; Gattozzi D; Musto P; Storto G
    Eur J Haematol; 2014; 92(5):382-9. PubMed ID: 24428392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma.
    Xie M; Zhai W; Cheng S; Zhang H; Xie Y; He W
    Hematology; 2016 Mar; 21(2):99-105. PubMed ID: 26183456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 6. Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma.
    Wu X; Pertovaara H; Korkola P; Vornanen M; Järvenpää R; Dastidar P; Eskola H; Kellokumpu-Lehtinen PL
    Acta Oncol; 2014 Aug; 53(8):1093-9. PubMed ID: 24960581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.
    Lee JW; Kang CM; Choi HJ; Lee WJ; Song SY; Lee JH; Lee JD
    J Nucl Med; 2014 Jun; 55(6):898-904. PubMed ID: 24711649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Value of
    Zhang YY; Chen WY; Cui YP; Gao XR; Hu JX; Li ZZ; Hu K
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1342-1249. PubMed ID: 30295248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.
    Song MK; Yang DH; Lee GW; Lim SN; Shin S; Pak KJ; Kwon SY; Shim HK; Choi BH; Kim IS; Shin DH; Kim SG; Oh SY
    Leuk Res; 2016 Mar; 42():1-6. PubMed ID: 26851438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
    Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
    Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants.
    Xie M; Wu K; Liu Y; Jiang Q; Xie Y
    Med Oncol; 2015 Jan; 32(1):446. PubMed ID: 25511321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of pretreatment metabolic tumor volume and total lesion glycolysis in hypopharyngeal squamous cell carcinomas.
    Roh JL; Kim JS; Kang BC; Cho KJ; Lee SW; Kim SB; Choi SH; Nam SY; Kim SY
    J Surg Oncol; 2014 Dec; 110(7):869-75. PubMed ID: 25088392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
    Vu CC; Matthews R; Kim B; Franceschi D; Bilfinger TV; Moore WH
    Nucl Med Commun; 2013 Oct; 34(10):959-63. PubMed ID: 23921784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma.
    Kim TM; Paeng JC; Chun IK; Keam B; Jeon YK; Lee SH; Kim DW; Lee DS; Kim CW; Chung JK; Kim IH; Heo DS
    Cancer; 2013 Mar; 119(6):1195-202. PubMed ID: 23212736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment.
    González-Barca E; Canales M; Cortés M; Vidal MJ; Salar A; Oriol A; Bargay J; Bello JL; Sánchez JJ; Tomás JF; Donato E; Ferrer S; Caballero D;
    Nucl Med Commun; 2013 Oct; 34(10):946-52. PubMed ID: 23880897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
    Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
    Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Tateishi U; Tatsumi M; Terauchi T; Ando K; Niitsu N; Kim WS; Suh C; Ogura M; Tobinai K
    Cancer Sci; 2015 Feb; 106(2):186-93. PubMed ID: 25495273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Importance of Bone Marrow Uptake on Baseline
    Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
    Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the prognostic values of
    Lim CH; Hyun SH; Moon SH; Cho YS; Choi JY; Lee KH
    Sci Rep; 2020 Jul; 10(1):12748. PubMed ID: 32728134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
    El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
    Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.